Raul Y Krauss

age ~62

from Chestnut Hill, MA

Get Report

Also known as:

Raul D Krauss
Raul M Krauss
Raul Kauss
Paul Krauss
Raul Crauss

Connected to:

Raul Krauss Phones & Addresses

Chestnut Hill, MA
Newton Center, MA
20 Holden St, Cambridge, MA 02138 • 6176617393

Work

Company:

Vertex pharmaceuticals
Jan 2007 to 2016
Position:

Head: multiple sclerosis disease area team

Education

School / High School:

Harvard Business School Online
2016 to 2016

Skills

Drug Discovery • Biotechnology • Neuroscience • Pharmaceutical Industry • Neurology • Neurobiology • Life Sciences • Cell Biology • Research • Molecular Biology • Consulting • R&D • Cell • Immunohistochemistry • In Vivo • Cell Culture • Drug Development • Pharmacology • Lifesciences • Clinical Development • Assay Development • Clinical Research • Immunology • Mammalian Cell Culture • Glia • Research and Development

Languages

English • Spanish • French

Industries

Biotechnology

Us Patents

Bmp-9 Compositions And Methods For Inducing Differentiation Of Cholinergic Neurons
view source
US Patent:

20050222028, Oct 6, 2005
Filed:

Dec 14, 2004
Appl. No.:

11/011791
Inventors:

Jan Blusztajn - Cambridge MA, US
Raul Krauss - Cambridge MA, US
R. Thies - Andover MA, US
International Classification:

A61K038/17
US Classification:

514012000
Abstract:

BMP-9 compositions and methods for their use are disclosed. The BMP-9 compositions act as a differentiating factor for the cholinergic phenotype of CNS neurons. The compositions may be used in the treatment of diseases and disorders caused by degeneration and/or malfunctioning of cholinergic neurons.

Cell Adhesion-Mediating Proteins And Polynucleotides Encoding Them
view source
US Patent:

20040249145, Dec 9, 2004
Filed:

Nov 7, 2003
Appl. No.:

10/704363
Inventors:

Karen Stark - Arlington MA, US
Alix Weaver - Northbridge MA, US
Heidi Hoffmann - Lunenberg MA, US
Raul Krauss - Newton MA, US
Kulvinder Saini - Haryana, IN
Dario Valenzuela - Houston TX, US
International Classification:

C07K014/705
C07H021/04
US Classification:

536/023500, 435/069100, 435/320100, 435/325000, 530/350000
Abstract:

The present invention provides multiple polynucleotide sequences from the same novel gene, the exons comprising the polynucleotide sequences, and the proteins encoded by the polynucleotide sequences. Three splicing variant polynucleotides were isolated from prostate tissue. The polypeptides, including the splicing variants, have a region of hydrophobicity indicative of a transmembrane domain and all three extracellular and cytoplasmic domains.

Triazoles For The Treatment Of Demyelinating Diseases
view source
US Patent:

20190185436, Jun 20, 2019
Filed:

Oct 17, 2018
Appl. No.:

16/162835
Inventors:

- Boston MA, US
Jingrong Cao - Newton MA, US
Meghan Elise Cockerill - Boston MA, US
Philip Noel Collier - Hingham MA, US
Elisabeth Doyle - Worcester MA, US
James Daniel Frantz - Belmont MA, US
Huai Gao - Arlington MA, US
Brian Anthony Goldman - Brookline MA, US
Anne-Laure Grillot - Milton MA, US
Wenxin Gu - Concord MA, US
James A. Henderson - Cambridge MA, US
Raul Eduardo Krauss - Chestnut Hill MA, US
Adrianne Lynn Kolpak - Watertown MA, US
Yusheng Liao - Lexington MA, US
Sanjay Shivayogi Magavi - Cambridge MA, US
David Messersmith - Somerville MA, US
Albert Charles Pierce - Cambridge MA, US
Emanuele Perola - Brookline MA, US
Elizabeth Jin-Sun Ryu - Newton MA, US
Joshua Syken - Jamaica Plain MA, US
Jian Wang - Newton MA, US
Michael Paul DeNinno - Gales Ferry CT, US
Francois Maltais - Tewksbury MA, US
International Classification:

C07D 249/14
C07D 405/12
C07D 403/14
C07D 403/04
C07D 401/12
C07D 401/04
C07D 405/14
A61K 31/4439
A61K 31/454
A61K 31/496
A61K 31/497
A61K 31/5377
A61K 31/4196
C07D 403/12
Abstract:

The invention relates to triazole compounds of formula I and I′ or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases:The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

Triazoles For The Treatment Of Demyelinating Diseases
view source
US Patent:

20160355488, Dec 8, 2016
Filed:

Jun 3, 2016
Appl. No.:

15/173177
Inventors:

- Boston MA, US
Jingrong Cao - Newton MA, US
Meghan Elise Cockerill - Boston MA, US
Philip Noel Collier - Hingham MA, US
Elisabeth Doyle - Worcester MA, US
James Daniel Frantz - Belmont MA, US
Huai Gao - Arlington MA, US
Brian Anthony Goldman - Brookline MA, US
Anne-Laure Grillot - Milton MA, US
Wenxin Gu - Concord MA, US
James A. Henderson - Weston MA, US
Raul Eduardo Krauss Irarrazaval - Chestnut Hill MA, US
Adrianne Lynn Kolpak - Watertown MA, US
Yusheng Liao - Lexington MA, US
Sanjay Shivayogi Magavi - Cambridge MA, US
David Messersmith - Somerville MA, US
Albert Charles Pierce - Cambridge MA, US
Emanuele Perola - Brookline MA, US
Elizabeth Jin-Sun Ryu - Newton MA, US
Joshua Syken - Jamaica Plain MA, US
Jian Wang - Newton MA, US
Michael Paul DeNinno - Gales Ferry CT, US
Francois Maltais - Tewksbury MA, US
International Classification:

C07D 249/14
A61K 31/496
C07D 405/14
A61K 31/497
A61K 31/454
C07D 401/04
A61K 31/4439
C07D 403/12
A61K 31/5377
C07D 401/12
C07D 405/12
A61K 31/4196
Abstract:

The invention relates to triazole compounds of formula I and I′ or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases:The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

Resumes

Vice President And Co-Founder | Head Of Biology

view source

Location:

Los Angeles, CA

Industry:

Biotechnology

Work:

Vertex Pharmaceuticals Jan 2007 - 2016
Head: Multiple Sclerosis Disease Area Team
Vertex Pharmaceuticals Mar 1, 2014 - 2016
Co-Head North America, Neurology Disease Area Team
Disarm Therapeutics Mar 1, 2014 - 2016
Vice President and Co-Founder | Head of Biology
Vertex Pharmaceuticals 2007 - 2012
Research Scientist and Senior Research Scientist
Biogen 2005 - 2005
Research Scientist, Neurobiology and Molecular Discovery

Education:

Harvard Business School Online 2016 - 2016
Harvard University 1997
Doctorates, Doctor of Philosophy, Neuroscience Harvard Business School Online 1975 - 1980
Harvard University;Phd, Neuroscience;1997;
Doctorates, Doctor of Philosophy, Neuroscience Harvard Medical School

Skills:

Drug Discovery
Biotechnology
Neuroscience
Pharmaceutical Industry
Neurology
Neurobiology
Life Sciences
Cell Biology
Research
Molecular Biology
Consulting
R&D
Cell
Immunohistochemistry
In Vivo
Cell Culture
Drug Development
Pharmacology
Lifesciences
Clinical Development
Assay Development
Clinical Research
Immunology
Mammalian Cell Culture
Glia
Research and Development

Languages:

English
Spanish
French